Experimental pill promises new hope for deadly pancreatic cancer

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a clinical trial. The drug targets a mutated protein present in over 90% of pancreatic cancer cases and showed fewer severe side effects, with patients reporting better quality of life.